Enabling pre-clinical program of NEW Chemical Entities (NCEs) and providing one stop solution to customize the product in rapid phase. The activities recorded in the electronic lab notebook enforces online documentation in accordance to principles of ALCOA+. Our value proposition: Discovery Research Quick access to the building blocks and key intermediates Time is essence of synthesis Enable the supply for discovery research 100g to few kilos
Early phase development Quick access to Drug substance for toxicology studies Phase appropriate PRD to enable the scale up Non GMP facility: Flexible operation and accelerated delivery
Infrastructure
- 300+ fume hoods
- Kilo lab with cylindrical reactor varying 5L to 50L capacity
- Reactors from 500 L to 5000 L in Hyderabad & Bangalore
- 50L autoclave a with 20kg/Cm2 design pressure
- Pressure Nutsche filter, vaccum tray dryer and 20L rotavapor for downstream process
- Huber unit to operate the process -20 to 150 degree Celsius
- Internal network of strategic business partners
- We also have a potent kilo lab
Scientific Expertise
- Qualified PhDs and Postdocs in organic chemistry
- 150+ scientists in chemistry and analytical services
- 10+ process engineers and process safety engineers
Chemistry capabilities
Expertise in
- Metal promoted cross coupling reaction
- Halogenation reactions
- High pressure hydrogenation
- Metal hydrate reactions
- Carbohydrates
- Lipids
- Peptides
- PEGylation
- Asymmetric synthesis
- Deuterated compound
- Heterocyclic chemistry
- Asymmetric hydrogenation
- Chiral synthesis
Analytical capability
- High-performance liquid chromatography with varying detectors
- Gas chromatography
- Mass triple quad, 1H NMR Bruker
- Differential scanning calorimeter
- Micro calorimeter
- Reaction calorimetry
Why Aurigene Non-GMP Pilot Facility Services?
Quick turnaround of sample delivery
A strong scientific and analytical team
Infrastructure for mg to kg synthesis
Large network of qualified strategic business partners
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Connect with our scientific experts for your drug discovery, development, and manufacturing needs
We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.
Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.
Resources
OCTOBER 01, 2024
PROTACs: Research for a life without cancer
PROTACs: Proteolysis-targeting chimeras (PROTACs) are a rapidly evolving field with promising applications in cancer, neurodegenerative diseases, and other conditions where the regulation of protein levels is crucial. PROTACs are a novel class of small molecules designed to target specific proteins for degradation by the ubiquitin-proteasome sys...
Read More
Advancement in personalized medicine and how the CRDMO industry is part of the solution
Personalized medicine is transforming the healthcare landscape by customizing treatment plans to individual patients’ unique genetic, clinical and environmental characteristics. These are effective and less invasive treatments for a wide range of conditions. Contract Research, Development and Manufacturing Organizations (CRDMOs) play an important role...
Read More
Cell Line Development
We enable development of stable and high yielding recombinant Mammalian and Microbial lines. ...
Read More
Case study: Tackling CYP 2C9 inhibition challenges
The Problem: Active compounds in a project were found to be highly potent inhibitors of CYP 2C9 The compounds selectively inhibited CYP 2C9 with IC50 values <100 nM There was no considerable inhibition of the other CYP isoforms Our Mitigation Approach: CYP 2C9 inhibition data was generated for a larger set of co...
Read More
Synthesis of Anti-covid Drug Nirmatrelvir Using Flow Chemistry
2022
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...
Read More-
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2005
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More -
Wang-OSO3H catalyzed green synthesis of bioactive isoindolo[2,1- a ]quinazoline-5,11–dione derivatives: An unexpected observation
2005
The sulphonic acid-functionalized Wang resin (Wang-OSO3H) was explored as a polymeric and recov- erable acidic catalyst for the synthesis of isoindolo[2,1- a ]quinazoline-5,11–dione derivatives under green conditions. Thus the Wang-OSO3H ...
Read More -
Polycyclic Aromatic Compounds: A Simple and Efficient [(n-Bu3Sn)2MO4]n Catalyzed Synthesis of Quinazolinones and Dihydroquinazolinones
2005
A novel unprecedented approach for the synthesis of various quinazolinones and dihydroquinazolinones has been using [(n-Bu3Sn)2MO4]n as a catalyst. The reaction has been screened ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market